Source comparison
Thymosin Alpha-1 for Hashimoto's Research: Protocol Comparison
Dosing Frequency 1.6mg twice weekly (Mon/Thu) 1.6mg twice weekly continuous 1.6mg twice weekly during 'on' cycles Twice-weekly spacing maintains TLR9 engagement without receptor saturation. More frequent dosing shows no added benefit Total Duration 24 weeks 48
This comparison does not assign a generated winner or score.
- Dosing Frequency
- 1.6mg twice weekly (Mon/Thu)
- 1.6mg twice weekly continuous
- 1.6mg twice weekly during 'on' cycles
- Twice-weekly spacing maintains TLR9 engagement without receptor saturation. More frequent dosing shows no added benefit
- Total Duration
- 24 weeks
- 48 weeks
- 6 months active + 3 months washout, repeated
- 24-week protocols demonstrate measurable antibody reduction; 48-week studies show sustained benefit but limited additional reduction beyond 6 months
- Antibody Reduction (Anti-TPO)
- 30–40% mean reduction
- 42–48% mean reduction
- 28–35% per cycle, plateaus after 2 cycles
- Diminishing returns after 6 months suggest immune recalibration reaches a new steady state rather than continuing linear reduction
- Levothyroxine Adjustment
- Required in 22% of patients at week 12–16
- Required in 38% of patients by month 9
- Required in 18% per cycle
- Dose reductions reflect decreased thyroid destruction, not peptide-induced hormone changes. TSH monitoring remains essential
- Cost (Research Supply)
- Approx. $480–600 total peptide cost
- Approx. $960–1,200 total peptide cost
- Approx. $640–800 per year (two cycles)
- Pulsed protocols offer cost-efficiency while maintaining most of the immunomodulatory benefit. Antibody rebound during washout is minimal (8–12% mean increase)
- Durability Post-Treatment
- Antibody rebound of 15–20% at 6 months post-treatment
- Antibody rebound of 10–15% at 6 months post-treatment
- Continuous modest benefit if repeated annually
- No protocol achieves permanent antibody elimination. Thymosin Alpha-1 modulates active disease but does not 'cure' the underlying genetic susceptibility